Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grossberg, S. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grossberg, S. E.
NEUROLOGY 2003;61:S21-S23
© 2003 American Academy of Neurology

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

Perspectives on the neutralization of interferons by antibody

Sidney E. Grossberg, MD

From the Department of Microbiology & Molecular Genetics, Medical College of Wisconsin, Milwaukee, WI.

Address correspondence and reprint requests to Dr. Sidney E. Grossberg, Department of Microbiology & Molecular Genetics, 8701 Watertown Plank Road, Milwaukee, WI 53226; e-mail: segrossb{at}mcw.edu

Interferon (IFN) neutralizing antibody (NAb) interferes with the binding of the IFN molecule to its cellular receptor, thereby preventing receptor activation required to trigger the cascade of signal transduction events that lead to the varied actions of IFN. IFN antibody neutralization is measured in an IFN bioassay using cultured human cells. Antibody results need to be represented in a reproducibly quantitative manner to know what proportion of patients treated with an IFN preparation form NAbs and whether the levels of antibody measured are likely to have clinically adverse effects; however, antibody titers have been reported in various ways. Extensive experimental and theoretical analyses of IFN-antibody neutralization reactions have provided the basis for establishing a defined international unit of IFN NAb, described herein, so that the data from different laboratories can be readily compared and interpreted.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.